Overlay Shares Hedged Large Cap Equity ETF (OVLH)
Live price chart, market sentiment, and community perspectives for Overlay Shares Hedged Large Cap Equity ETF (CBOE: OVLH).
Live price chart, market sentiment, and community perspectives for Overlay Shares Hedged Large Cap Equity ETF (CBOE: OVLH).
On our desk, we've been tracking OVLH's updated strategy shift effective December 31, 2025. Moving toward long-term capital appreciation while systematically mitigating market risk has caught the attention of several institutional clients looking for uncapped large-cap beta without total unhedged exposure. With $114.39 million in total assets as of mid-2026, it's carving out a solid niche.
As a risk manager reviewing the recent semi-annual report for OVLH up to February 2026, the fund's use of long-term out-of-the-money put options provides a clear buffer against significant market drawdowns. However, analysts must weigh the net expense ratio of 0.80% against the protection gained, especially in low-volatility regimes where option decay can weigh on performance.
Looking at the Q2 2026 institutional filings, 24 funds have committed $95.1 million into OVLH. The dynamic of 5 new positions opened and 7 increases indicates that smart money sees value in its structural put-buying overlay, especially given recent observations on elevated constituent dispersion beneath the surface of headline index volatility.
From a quantitative perspective, OVLH maintains a low portfolio turnover around 23% alongside a 30-day SEC yield of roughly 0.29%. The fund's ability to mirror large blend characteristics while deploying laddered, out-of-the-money put options offers an interesting alternative to traditional covered-call writing that typically caps upside returns.
When discussing portfolio construction with clients, I emphasize OVLH's unique positioning: it seeks to avoid the timing complexities of traditional hedging. By purchasing long-term puts directly, it keeps equity exposure completely uncapped. It's a vital talking point for advisors evaluating risk-adjusted returns in the US Fund Equity Hedged category.
Explore plasma cleansing, somatic organ swaps, and BCI.